AI and Estimated Date of Delivery

The main pharmaco-therapeutic effects: anti arrhythmic effect, acting on ?1 and ?2 - Adrenoceptors; has significant antiarrhythmic action mechanism which is to increase the action potential duration and refractory period at all sites conducting system heart disease (class III antiarrhythmic drugs) reduces heart rate and myocardial skorotlyvist reduces the sine node automatism, slows AV-conduction, blocking the ?2 - adrenoreceptors, increases the tone of smooth muscles of bronchi and vessels. splayed for use drugs: SUPRAVENTRICULAR tahiarytmiyi accompanied by clinical symptoms (including AV-/vuzlovi/paroksyzmalni tachycardia in WPW with-E or paroxysms of atrial fibrillation), prevention of paroxysms and flicker atrial flutter after restoration of sinus rhythm, ventricular cardiac rhythm disturbance, splayed by clinical symptoms (tahiarytmiyi) and Prevention of proven effectiveness; arrhythmia caused by excessive circulation catecholamines or increased sensitivity to catecholamines. The main pharmaco-therapeutic effects: dezahrehantna, analgesic, antipyretic, anti-inflammatory, inhibits the aggregation platelets by blocking thromboxane A2 synthesis, splayed mechanism of action is irreversible enzyme inactivation cyclooxygenase (COX-1) indicated inhibitory effect particularly pronounced for platelets because they are not capable of resynthesis given enzyme, splayed recognizes that detects Acetylsalicylic acid and other inhibiting effects on platelets, due to specified effects, its use in many vascular-vascular diseases splayed . Side effects and complications in the use of drugs: mikrovidkladennya in the area of the cornea, blurred vision in the form Torsades de pointes Peak Acid Output halo of bright light or zatumanyuvannya vision, optic nerve neuropathy; photosensitization in long-term use of high daily doses, erythema, skin splayed exfoliative dermatitis, hair loss, increased T4 with normal or slightly reduced levels of T3 in the absence of clinical signs dysthyrosis, classical form of hypothyroidism; hyperthyroidism; in the elderly may experience mental disorders or even thyrotoxicosis, diffuse interstitial or alveolar pneumopathy and obliterative bronchiolitis with pneumonia, pleurisy on the background of interstitial pneumonia, bronchospasm, G. Pharmacotherapeutic group: S07AA07 - selective antagonists of ?-blockers. Contraindications to the Proximal Interphalangeal Joint of drugs: sinus bradycardia and heart block CA-correction in the absence of artificial pacemaker heart (pacemaker). Method of production splayed drugs: Table. of 0,2 g, Mr injections for 5% to 3 ml (150 mg) in the amp. MI, shock, arterial hypotension; AV-block II and III degree; CA-blockade; SSSV; bradycardia (heart rate of less than 50 beats / min) interval prolongation of QT; obliterative vascular disease, obstructive disease airway, metabolic acidosis, swelling of the throat, severe allergic rhinitis, untreated phaeochromocytoma, and hypokalemia hipomahniyemiya, hypersensitivity to the drug and sulfonilamidiv, a rare hereditary form of galactose intolerance, the deficit lactase or glucose-halaktozna malabsorption, for patients who are treated Solatol (excluding intensive medication) is contraindicated in / to the introduction of calcium antagonists like verapamil and diltiazem, or other antiarrhythmic drugs. Cardiopulmonary resuscitation of cardiac arrest, which occurred due to ventricular fibrillation, and which is resistant to external countershock. Dosing and Administration of drugs: standard recommended dose for adults is 200 mg 3 g / day for 8-10 days, in some cases, early treatment can be used higher doses (4-5 Table / splayed taking over a short period of time Hemoglobin under ECG control, supportive treatment (should be used minimally effective dose) - depending on the reaction patient on the drug maintenance dose for adults can be from ? Table / day (1 tab. Parenterally in severe disturbances of cardiac rhythm when treatment by oral preparatuu inappropriate, such as: Atrial fibrillation with high ventricular rate cuts; tachycardia associated with c-IOM WPW; documented symptomatic ventricular arrhythmias that lead to disability.